SerpinPC is a recombinant protein commercialized by Centessa Pharmaceuticals, with a leading Phase II program in Hemophilia B (Factor IX Deficiency). According to Globaldata, it is involved in 3 clinical trials, of which 2 are ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of SerpinPC’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for SerpinPC is expected to reach an annual total of $128 mn by 2038 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
SerpinPC is under development for the treatment of haemophilia A and haemophilia B. It is administered through the subcutaneous route and intravenous route. It is an engineered serpin that acts by targeting coagulation factor XIV (activated protein C (APC).
Centessa Pharmaceuticals Overview
Centessa Pharmaceuticals is a next-generation biopharmaceutical firm aiming to reinvent the medication development process. The company is headquartered in Cambridge, England, the UK.
The operating loss of the company was US$212.3 million in FY2022, compared to an operating loss of US$374.1 million in FY2021. The net loss of the company was US$216.2 million in FY2022, compared to a net loss of US$381.1 million in FY2021.
For a complete picture of SerpinPC’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.